BiotechSwings
$PYXS is still running imo
up 12.8% this morning to 1.89 after Thursday closed up 19.1% at 1.68 on 1.8 million shares
MICVO Phase 1 in head and neck cancer after prior therapy, 33 evaluable patients
39% confirmed responses, 94% disease control, median PFS 6.7 months vs 4.2 months on prior therapy, one complete response in there too
William Blair upgraded it to Outperform this morning, HC Wainwright kept Buy at 8, and Phase 3 is planned for mid 2027
old options in this setting answer under 15% of the time. 39% is not a small beat ngl
6
